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Introduction and aims. It is well established that soft tissue sarcomas (STSs) are more eﬀectively treated in a specialist centre.
However, delays in time taken for a patient to be referred to a specialist centre may lead to a poorer prognosis. This study aims
to identify the length of these delays and where they occur. Patients and methods. Patients with a proven STS were included. They
were recruited from both outpatient clinics and from the surgical ward of the Royal Orthopaedic Hospital (Birmingham, UK). A
structured interview was used to take a detailed history of the patients’ treatment pathway, before arriving at the specialist centre.
Dates given were validated using the case notes. Results. The median time for the patient to present to a specialist centre from
the onset of symptoms was 40.4 weeks. The median delay until presentation to a medical professional (patient delay) was 1.3
weeks. Median delay in referral to a specialist centre (service delay) was 25.0 weeks. Discussion. Medical professionals rather than
patientscontributethegreatestsourceofdelayinpatientsreachingaspecialistcentrefortreatmentofSTS.Adherencetopreviously
published guidelines could decrease this delay for diagnosis of possible sarcoma. Steps should be taken to refer patients directly to
a diagnostic centre if they have symptoms or signs suggestive of STS.
Copyright © 2008 G. D. Johnson et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Soft tissue sarcomas (STSs) are a rare group of cancers with
approximately2200diagnosedintheUKeveryyear[1].They
account for approximately 1% of all cancers and 2% of all
cancer deaths [2]. Survival rates are approximately 50% at 5
years and are related to grade, depth, and size of tumour at
diagnosis.
Due to the rarity and high mortality rate of STS, guide-
lines have been introduced by the Department of Health
for their early diagnosis. The guidelines state that any lump
that is either: ≥5cm in size and/or deep to the fascia and/or
painful and/or increasing in size should be referred to a
diagnostic centre for investigation and to a surgical centre
for management [3]. However, recent evidence suggests that
these guidelines are not well implemented, resulting in inad-
equate management of these tumours and delays in referral
[4–7].
In the Trent Cancer Registry region, median size at pre-
sentation to the sarcoma service was 8cm (range: 0.3–45cm)
[8] and data from the Scandinavian Sarcoma Group Regis-
ter shows a median size of 7cm at presentation, varying with
age, with a larger median tumour size in older patients [9].
At our centre, however, the median size of tumour seen at
ﬁrst presentation is 9cm. Thus, patients presenting to our
centre have tumours nearly twice the size recommended by
theguidelines.Thisdelayinpresentationtospecialistservices
could be due to either unwillingness of patients to present
initiallyortodelaysafterinappropriateprimaryorsecondary
referrals.
Due to their rarity, referral patterns for STS are often cir-
cuitous and are manifested by delays in presentation and re-
ferral. Lack of experience with these tumours is the oft-cited
reason for delayed referral practice and inadequate manage-
ment. With an average General Practitioner (GP) seeing only
1 STS in 20 years of practice, this claim is easily substanti-
ated [10]. Referral to a General or Othopaedic Surgeon often
increases delays to deﬁnitive treatment as, because of their
rarity, a malignant diagnosis is a low clinical suspicion. As a
result, inappropriate surgical techniques are often employed:
lesions may be excised under the assumption that they are
benign, with inadequate surgical margins [11, 12]. A recent2 Sarcoma
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Figure 1: Size of tumour at presentation to ROH.
study found that 50% of patients referred to their Sarcoma
Service had received some surgical intervention at a nonspe-
cialist centre [11].
Several papers have described delays in referral of pa-
tients with STS for treatment. These found that medical pro-
fessionals were the source of the greatest delay. However, GPs
and hospital consultants were not considered separately and
all the studies identiﬁed a time period which the authors
thought constituted “delay,” only going on to analyse those
patients with delay [4–6]. However, this fails to give an accu-
rate impression of the actual timescale.
Current guidelines in the UK state that any patient with
suspectedcancershouldbeseenbyaspecialistwithin2weeks
ofreferral[13].Atpresent,thereisnodataondelayintheUK
attributabletopatients,andmedicalprofessionaldelayisdif-
ﬁcult to quantify, as the only UK paper on the subject judged
that delay was anything longer than 3 months [6]. This study
aims to bring clarity to the situation, which is essential to
the development of further training of medical professionals
in the UK. Recent literature suggests that obesity can cause
a worse prognosis and delays in presentation in cancer pa-
tients [14]; therefore we also plan to identify whether any pa-
tient factors (BMI, Social Class and Literacy Levels) have any
eﬀect on delay in presentation or size of tumour at diagnosis.
2. PATIENTS AND METHOD
A total of 162 patients with a conﬁrmed diagnosis of Soft
Tissue Sarcoma were recruited from a combination of the
outpatient clinic and from the surgical ward at the Royal
Orthopaedic Hospital (Birmingham, UK) between January
2005andMay2005.Inordertomaximisepatientnumbersin
the study, a combination of followup patients and new refer-
rals were included. Appropriate ethical approval was gained.
Patients were consented by their doctors and the study was
furtherexplained tothembyaresearcheratwhichpoint they
were given an explanatory letter. A structured interview was
Table 1: Histological diagnosis.
Diagnosis Frequency Percentage
Liposarcoma 39 24.1
Myxoﬁbrsarcoma 21 13.0
Leiomyosarcoma 12 7.4
Spindle cell sarcoma 11 6.8
Synovial sarcoma 11 6.8
Pleomorphic sarcoma 7 4.3
MFH 6 3.7
MPNST 5 3.1
Other 50 30.9
Total 162 100.0
used to gather the study information, which was completed
by one member of the research team.
2.1. Demographics
We collected standard demographic information about pa-
tient age, sex, histological diagnosis, size of tumour at pre-
sentation and which features suggestive of sarcoma from the
guidelines the patient had, if any.
2.2. Timedelay
We measured duration of symptoms before a patient pre-
sented to a medical professional (MP), by asking the patients
to recall when they ﬁrst noticed the lump. We asked the pa-
tients to recall the dates when they ﬁrst saw a medical profes-
sional(normallyaGP)andwhentheywerereferredtosome-
one, either a district general hospital (DGH) or the Royal
Orthopaedic Hospital (ROH). For those patients who were
referred to a DGH, we asked them to then recall when they
were then referred to the ROH.
Alldateswereconﬁrmedwithdatesinthepatients’notes.
Referral date to the ROH was the only date that could be
conﬁrmed in all cases. This was therefore used to calculate
the accuracy of the dates given by each patient, by compar-
ing the ROH referral date they speciﬁed with the actual date
recorded in the notes.
Patients were asked to recall the management of the ﬁrst
medical professional they saw and the subsequent clinicians.
As a result, we calculated the number of inappropriate and
inadequateproceduresperformed.Wealsorecordedwhether
the patient had any cross-sectional imaging or a biopsy when
managed at a DGH.
2.3. Associations
Age, sex, patients’ postal code, and the age at which they left
full-time education were recorded. Using the Townsend de-
privation scale, we calculated social deprivation from a pa-
tient’s postal code; and literacy levels were calculated from
the age they left full-time education.
We also recorded the patients’ height in centimetres and
weight in kilos. Height was recorded at interview, as this willG. D. Johnson et al. 3
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Figure 2: The median patient.
not have signiﬁcantly changed since they ﬁrst had their Soft
Tissue Sarcoma. Weight was recorded from the operation
record to ensure that we recorded the weight of the patient
as close to diagnosis as possible. Using this information we
then calculated each patient’s body mass index.
3. STATISTICAL ANALYSIS
Simpledescriptivestatisticswereperformedonthedata.Lin-
ear regressions and correlations were performed to test for
associations.Itwaspredictedthatthedatawouldnotfollowa
normal distribution and therefore nonparametric tests were
used for comparisons (Mann-Whitney-U test). The median
has been chieﬂy used as the method of comparison because
a number of patients had excessively long delays, which have
skewed the mean. However, the mean has been provided for
completeness.
4. RESULTS
Of the 162 patients included, the mean age at diagnosis was
53years(range16–88).Thesexdistributionwas49.3%male:
50.7% female. The median size of tumour at diagnosis was
8cm (mean 8.91cm, range 0–26cm) (see Figure 1). His-
tological subtypes followed the expected distribution with
the commonest being Liposarcoma 24.1%, Myxoﬁbrosar-
coma 13.0%, and Leiomyosarcoma 7.4%. A percentage of
55.5% of lumps were deep, 43.2% high-grade, and 39.2%
intermediate-grade. 88% of patients had at least one of the
features that are suspicious of sarcoma at ﬁrst presentation
to a medical professional. Site of tumour also followed the
expected distribution, with 42.5% aﬀecting the thigh, 20%
the lower leg, 14.6% the forearm, 13% the upper arm, 9.2%
the trunk, and 1.5% aﬀecting the hand.
The median time for a patient to be referred to the ROH
from the onset of symptoms was 40.4 weeks (mean 112.3
weeks). Only 14.6% were referred within 3 months of the
onset of symptoms and 44.9% of patients took longer than
1 year to be referred to the ROH from onset of symptoms
(Table 1).
The median time for a patient to initially present to a
medical professional from onset of symptoms was 1.3 weeks
Table 2: Tumour grade and depth.
Grade Frequency Percentage
High 54 43.2
Intermediate 49 39.2
Low 22 17.6
Deep 61 55.5
Subcutaneous 49 44.5
(mean 28.6 weeks). 60.6% of patients consulted a medical
professional (91.6% of which were GPs) within 1 month.
72.5% had consulted within 3 months. 12.5% of patients
waited longer than one year before consulting; the longest a
patient waited before seeking medical advice was 674 weeks
(13 years). From ﬁrst presentation to a medical professional,
the median time for a patient to be referred to the ROH was
25.0 weeks (mean 83.1 weeks). Only 11.3% of patients were
referred to the ROH within 1 month and 28.9% within 3
months. 32.7% of patients took longer than 1 year to be re-
ferred to the ROH for investigation and treatment (Table 3).
47% of patients were referred to a consultant the ﬁrst
time the patient presented. 51.0% were referred within 1
month and 60.9% within 3 months. 21.2% of patients took
longer than 1 year to be referred. 9 of the 162 patients were
referred directly to the ROH. The remaining 153 were re-
ferred to a local DGH and 37.3% of patients were referred to
the ROH by the consultant they saw within 1 month. 63.3%
had been referred within 3 months. 12.7% of patients man-
aged by a consultant in a DGH took longer than 1 year to be
referred to the ROH.
The 62 patients who were reassured by the ﬁrst medical
professional consulted took a mean of twice as long to be
referred to another, more specialised, medical professional
(P<. 0001). The median time for a patient who had been
reassured to be referred increased nearly 16 folds, to 38.3
weeks. Although the number of patients is too small for a
statistically signiﬁcant diﬀerence to be calculated (n = 11), it
appears that the decision to obtain an X-ray was related to an
increased time for referral from the GP to hospital (median
6.7 weeks) (Table 2).4 Sarcoma
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Figure 3: Flow chart of delay.
Performing an MRI or biopsy was related to a substantial
decrease in mean time to refer to the ROH, although median
time was slightly increased by performing biopsy. Perform-
ing surgery, whether or not they had an MRI &/or biopsy,
showed a highly signiﬁcant (P<. 0001) increase in the time
taken for a patient to be referred to the ROH. The 35 pa-
tients who had surgery without biopsy took nearly 3 times
longer to be referred to the ROH than the study mean and
median (P<. 0001). The 4 patients who had surgery hav-
ing already had a biopsy took a median 15.2 weeks (mean
24.3 weeks) longer, longer to be referred to the specialist cen-
tre. Only 3 patients were reassured by the DGH consultants
so the diﬀerence is not statistically signiﬁcant, but the mean
delay was nearly 7fold longer and median delay was nearly
27fold longer (Table 2).
The mean BMI of the patients studied was 26.6 (range:
18–45.8). The mean age that patients had left full-time edu-
cation was 16.9 and the mean Townsend score was −0.8373.
No association between any of these factors and either pa-
tient delay or medical professional delay was identiﬁed. No
association with BMI and size of tumour at presentation was
identiﬁed.TheonlyfactorthathadanycorrelationwithdelayG. D. Johnson et al. 5
Table 3: Summary of delays.
Mean Median Min. Max. % in 1 month % in 3 months % in 1 year % >1 year
Weeks
Stage 1 28.6 1.3 0.0 674.0 60.6 72.5 87.5 100.0
Stage 2 35.8 2.4 0.0 552.4 51.0 60.9 78.8 100.0
Stage 3 5.6 2.2 0.0 208.7 68.4 90.8 99.3 100.0
Stage 4 44.9 6.9 0.0 1065.3 37.3 63.3 87.3 100.0
MP delay 83.1 25.0 0.0 1083.3 11.3 28.9 67.3 100.0
Overall time 112.3 40.4 0.4 1089.3 3.8 14.6 55.1 100.0
Table 4: Medical professional delay breakdown.
Action
n = Mean Median Min. Max. % in 1 month % in 3 months % in 1 Year % >Year
Weeks
Time to ﬁrst
referral if
MP1
Overall 162 35.8 2.4 0 552.4 51.0 60.9 78.2 100.0
Reassures Patient 62 70.4 38.3 1.9 552.4 6.5 24.2 54.8 100
Sends patient to A&E for X-
ray
11 53.7 6.7 0 405.1 45.5 63.6 81.8 100
Time until
patient
referred to
the ROH if
2nd MP
Overall 162 44.9 6.9 0.0 1065.3 37.3 63.3 87.3 100.0
Reassures 3 308 185.3 79 659.4 0 0 0 100
Performs MRI 76 28.2 6.7 0 991.3 39.5 63.2 93.4 100
Performs biopsy 20 19.1 7.43 0.9 148.9 35 65 90 100
Peforms biopsy and MRI 4 7.1 5.9 1.3 15.3 50 75 100 100
Performs surgery with prior
biopsy
4 69.2 22.1 2.1 230.6 25 50 75 100
Performs surgery without
prior biopsy
44 120 18.3 2.6 1065.3 9.1 29.5 75 100
Performs surgery without
prior biopsy or MRI
32 124 17.9 2.6 1065.3 9.4 37.5 71.9 100
was the size of the tumour at ﬁrst presentation, where with
increasing size of tumour, the time taken to refer to the ROH
decreased (P = .022). There was no signiﬁcant diﬀerence in
time to presentation based on tumour site.
5. LIMITATIONS
The main limitation with this study is that it relies largely
on patient recall of signiﬁcant dates in their history and this
is liable to bias. However, in order to minimise this eﬀect,
dates of referral given by the patient were compared in all
cases with those in the notes. We found that there was no
signiﬁcant diﬀerence between these dates.
The population studied is an already biased population,
as we only studied patients diagnosed with sarcoma in a ter-
tiary referral centre. We are unable to take into account those
who have had their sarcomas managed elsewhere.
6. DISCUSSION
Current guidelines state that any patient with suspected can-
cer should be seen by a specialist within 2 weeks of ﬁrst pre-
sentationtoamedicalprofessional,normallyaGeneralPrac-
titioner. In the case of Soft Tissue Sarcoma, patients should
be referred to a specialist centre for further investigation and
management.
The most recent research on delays in the referral and di-
agnosisofSTShasidentiﬁedsigniﬁcantdelaysduetomedical
professionals. However, these papers set a ﬁxed time period
considered as “delay” being 1 month and 3 months [4–6].
The analysis then considers only those who have been found
to have a delay, thereby giving an inaccurate impression of
the actually timescale in the study patients. For this analysis,
no limit has been used to deﬁne “delay” and all medians and
means used contain all patients, including those who did not
suﬀer any delay.
Nearly 73% of patients presented to a medical profes-
sional (91.6%GP) within 3 months of the onset of symp-
toms, with a median time of 1.3 weeks (Table 3). This shows
that, although some patients are more willing to tolerate
symptoms, in general, patients present quickly to a medical
professional and therefore do not contribute signiﬁcantly to
delay in reaching a specialist centre for treatment.
The previous literature highlights general practitioners
as the most common source of delay in those patients who
were deﬁned as “delayed.” However, these studies identiﬁed
only 20% [5] and 27% [4]o fp a t i e n t sa sd e l a y e d .F u r t h e r
analysis of these patients revealed that GPs were responsible
in the majority of those cases. This study has demonstrated6 Sarcoma
that, using median time as a method of comparison, GPs are
actually quicker at referring to someone more specialised,
with Figure 2 the median patient being referred within 2.4
weeks of presentation, compared with 6.9 weeks for DGH
consultants. However, when examining the percentage of pa-
tients referred within 1 month and then 3 months, consul-
tants eventually appear to be as eﬃcient as GPs. Although
only 37.3% are referred within 1 month compared to 50.1%
for GPs, in a 3-month period 63.3% of patients under the
care of a consultant will be referred, compared to 60.9% of
patients under the care of a GP. Additionally, when compar-
ing the percentage of patients who took longer than 1 year to
be referred, it appears that DGH consultants are perform-
ing better than GPs, with 12.7% of patients taking longer
than 1 year, compared to 21.2% of GP patients (Figure 3).
This diﬀerence between GPs and DGH consultants is possi-
bly due to the ordering of investigations by consultants and
waiting for followup appointments. However, once the re-
sults of these investigations have been obtained, it seems that
referral is prompt; the 76 patients who were given an MRI
by their DGH consultant were actually referred slightly more
quicklythanthosewhowerenot(6.7weeksversus6.9weeks)
(Table 2).
It seems that the majority of GPs are referring promptly,
but they are referring to the wrong specialists. However, a
goodproportion(40%)ofGPsstilltakesover3monthstore-
fer to anyone, which is a problem that needs to be addressed.
The degree of delay is somewhat dependant on the initial ac-
tion of the GP. The 62 patients who were initially reassured
bytheirGPtooksigniﬁcantlylongertobereferredthanthose
who were not (Table 4). If they have been reassured that a
lump is benign, it may then take patients a long time to rep-
resent to the GP, thereby increasing time to referral.
Theﬁguresforpatientswhohavehadasurgicalinterven-
tion in a DGH are particularly interesting. It has been widely
documented that surgical intervention and investigation that
is not carried out in a specialist centre for sarcomas is asso-
ciated with a worse prognosis in terms of survival and local
recurrence. The interventions carried out are frequently in-
correct, as the consultants are unaware of the diagnosis; the
so-called “whoops procedure.” 48 patients had surgery at a
DGH, of which 4 had a biopsy before diagnosis. 44 had no
biopsy before excision, and 32 had no cross-sectional imag-
ing. What was particularly worrying was that these patients
took a mean and median 3 times (P<. 001) longer to be
referred to the ROH than those who were not operated on
(Table 2). Therefore, not only are these patients receiving
inappropriate and unnecessary surgery, but they are taking
longer to be seen and treated by the specialists of choice. In
mostcases,thepossibilityofmalignancyhadneverbeencon-
sidered, possibly increasing the waiting time for the opera-
tion.
We calculated BMI, recorded postal code to use the
Townsend social deprivation score, and recorded the age at
which patient left full-time education. The hypothesis was
that patients with a higher BMI would take longer to present,
as would people living in more deprived areas or with earlier
age of having left full-time education. None of these factors
were found to correlate with delay. The only factor that was
associated with delay was that of tumour size at ﬁrst presen-
tation; as tumour size increased, time to referral to the Royal
Orthopaedic Hospital decreased.
In terms of compliance with the recommended 2-week
referralguidelinesforsuspectedcancer,only3.8%ofpatients
were seen at the ROH within those 2 weeks. All of these pa-
tients were referred directly to the ROH from the GP; none
tookthetypicalrouteviaaDGH.Thisaccountsfor6patients
of the 9 patients who were referred directly to the ROH.
7. CONCLUSION
There is considerable medical professional delay in the man-
agement of soft tissue sarcoma. The fact that 88% of patients
had at least one of the guideline features for referral to a spe-
cialist centre at ﬁrst presentation suggests that knowledge of
the guidelines is poor. Increased education, not only of hos-
pital staﬀ and general practitioners but especially at medical
schools, is essential to ensure that patients are rapidly and
correctly referred. The ideal pathway from GP to specialist
centre needs to be emphasised, so that patients do not get re-
ferred to a DGH, where inappropriate and ineﬀective treat-
ment is often used.
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